TL
Insider
Tien-Li Lee
Chief Executive OfficerTien-Li Lee (Chief Executive Officer) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Aardvark Therapeutics, Inc. (AARD). Across 1 priced purchase filing, the average 21-session return was +3.1% from execution and -3.6% from disclosure (delay-adjusted; derived). The largest single filing was $101K of AARD (7,000 sh × $14.48, as filed), executed Dec 11 2025.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+3.1%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
-3.6%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells
Median delay
1d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$101K
shares × price, as filed
Last traded
Dec 11 2025
Filed Dec 12 2025
Median ADV $1.3M across their filed names
Open performance→Volume by month
Buys $366K
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Sector per market data · by filing · past 12 months
Most traded names
AARDRecent filings
AARDPURCHASE
Aardvark Therapeutics, Inc.
View filing →
$101K7,000 sh × $14.48
Exec Dec 11 2025
Filed Dec 12 2025 · 8:30 PM ET AARDPURCHASE Aardvark Therapeutics, Inc. View filing → $265K
16,542 sh × $16.00
Exec Feb 14 2025
Filed Feb 19 2025 · 5:30 PM ET